Although molecular targeted therapy have not yet proven effective in SCLC, we detected some well-known oncogenic driver mutations including PIK3CA (9/49) [24], KIT (1/49) [25], and BRAF (2/49) [26], which suggested opportunities for more targeted therapeutic approaches. Here, BRAF is linked to small cell lung carcinoma.